Regencell Bioscience Holdings Ltd (RGC) stock
RGCNasdaqMedicinal Chemicals & Botanical Products
$4.18−0.18 (-4.13%)
Close on Nov 20, 2026Market cap $2.07BP/E –Yield –
Regencell Bioscience net income
Net income is the profit left for shareholders after every expense, interest and tax.
For fiscal 2026 it was -$11.70M. The highest annual figure on record is -$390.99K in fiscal 2019.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -$11.70M | – |
| FY2025 | Jun 30, 2025 | -$3.58M | – |
| FY2024 | Jun 30, 2024 | -$4.30M | – |
| FY2023 | Jun 30, 2023 | -$5.87M | – |
| FY2022 | Jun 30, 2022 | -$7.45M | – |
| FY2021 | Jun 30, 2021 | -$1.35M | – |
| FY2020 | Jun 30, 2020 | -$812.37K | – |
| FY2019 | Jun 30, 2019 | -$390.99K | – |
See a number that looks wrong?